Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein
- PMID: 7831341
- PMCID: PMC42796
- DOI: 10.1073/pnas.92.2.631
Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein
Abstract
The hypervariable region 3 (V3) within the disulfide-bridged loop of the envelope protein of the human immunodeficiency virus type 1 (HIV-1) contains an amino acid sequence that was defined as a principal neutralizing determinant (PND). A 19-amino acid residue consensus sequence (designated V3C) predicted from the PND sequences of 245 isolates as well as a sequence from the PND of the WMJ2 HIV-1 isolate (designated V3M) were expressed on the variable region of murine-human immunoglobulin (Ig) chimeras that were designated Ig-V3C and Ig-V3M, respectively. The HIV-1 sequences on the Ig chimeras preserved their antigenicity and interacted with antibodies specific for peptides encompassing the V3C and V3M sequences. In baboons, Ig-V3C and Ig-V3M induced antibodies that bound V3C and V3M peptides as well as the glycoprotein gp120 envelope protein of HIV-1 MN isolate. In addition, the baboons' antisera were able to prevent infection of CD4 SupT1 susceptible T cells by HIV-1 MN. Finally, Ig-V3M chimeras were able to stimulate in vitro production of antibodies specific for the HIV-1 envelope-derived peptides by lymphocytes from HIV-1-infected human subjects.
Similar articles
-
The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.Virology. 1998 Nov 10;251(1):59-70. doi: 10.1006/viro.1998.9392. Virology. 1998. PMID: 9813203
-
Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.Biol Chem. 1999 Mar;380(3):353-64. doi: 10.1515/BC.1999.047. Biol Chem. 1999. PMID: 10223338
-
Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.J Virol. 1992 Jul;66(7):4003-12. doi: 10.1128/JVI.66.7.4003-4012.1992. J Virol. 1992. PMID: 1602531 Free PMC article.
-
Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S47-52. AIDS Res Hum Retroviruses. 1994. PMID: 7865333 Review.
-
Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.Antibiot Chemother (1971). 1994;46:48-61. doi: 10.1159/000423633. Antibiot Chemother (1971). 1994. PMID: 7826039 Review. No abstract available.
Cited by
-
Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing.J Exp Med. 1997 Mar 17;185(6):1043-53. doi: 10.1084/jem.185.6.1043. J Exp Med. 1997. PMID: 9091578 Free PMC article.
-
The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10296-301. doi: 10.1073/pnas.181336898. Epub 2001 Aug 21. Proc Natl Acad Sci U S A. 2001. PMID: 11517321 Free PMC article.
-
Epitope-specific tolerance induction with an engineered immunoglobulin.Proc Natl Acad Sci U S A. 1996 May 14;93(10):5019-24. doi: 10.1073/pnas.93.10.5019. Proc Natl Acad Sci U S A. 1996. PMID: 8643522 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials